Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XERS - Xeris Biopharma Holdings Inc


IEX Last Trade
2.805
0.005   0.178%

Share volume: 781,944
Last Updated: Fri 30 Aug 2024 09:59:47 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$2.80
0.01
0.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
30%
Profitability 15%
Dept financing 25%
Liquidity 75%
Performance 35%
Company vs Stock growth
vs
Performance
5 Days
-2.43%
1 Month
13.31%
3 Months
26.58%
6 Months
-6.95%
1 Year
22.71%
2 Year
74.53%
Key data
Stock price
$2.80
P/E Ratio 
-7.03
DAY RANGE
N/A - N/A
EPS 
-$0.42
52 WEEK RANGE
$1.46 - $3.26
52 WEEK CHANGE
$0.19
MARKET CAP 
418.687 M
YIELD 
N/A
SHARES OUTSTANDING 
148.999 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,148,509
AVERAGE 30 VOLUME 
$1,629,059
Company detail
CEO:
Region: US
Website: xerispharma.com
Employees: 360
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Recent news